genedrive plc (AIM: GDR) expects to report total income of £1.4 million for the year ended 30 June 2026, up from around £1.0 million in FY25 and in line with board expectations.
The point-of-care pharmacogenetic testing company said adoption of its MT-RNR1 and CYP2C19 tests continued to expand across the NHS and international markets.
The Genedrive® MT-RNR1 ID Kit is now in use across more than 20 neonatal intensive care units in the UK and internationally, with more than 13,000 babies tested and over 40 identified as being at risk of irreversible antibiotic-induced hearing loss.
Around 25 additional NHS business cases are progressing through local approval processes, while NHS England has begun pre-market engagement ahead of expected final NICE guidance in around July 2027.
The Genedrive® CYP2C19 ID Kit is currently being used or evaluated at approximately 15 sites and is in routine clinical use at major stroke units including Salford and Southmead Hospital.
Genedrive has also partnered with Thermo Fisher Scientific to develop a laboratory-based CYP2C19 test for use on the QuantStudio 5Dx platform.
International progress includes four pilot centres in Spain, a three-year CYP2C19 commercial contract in the UAE and continued engagement with healthcare authorities in Saudi Arabia.
The company said its planned US FDA 510(k) submission for CYP2C19 has been delayed from the previously anticipated June 2026 timeframe while external studies generate and validate the required data.
Genedrive ended June with approximately £3.0 million in cash following a £4.9 million net equity raise in March.
Chief executive Dr Gino Miele said the company was in its strongest commercial and operational position to date and was focused on accelerating adoption over the next 12 months.
